ArticleJournal of cachexia, sarcopenia and muscle2015
Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib.
Article in Journal of cachexia, sarcopenia and muscle, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02877368 (Sarcopenia in Patients With Gastrointestinal Stromal Tumours), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sarcopenia in Patients With Gastrointestinal Stromal Tumours
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.Internal and emergency medicine · 2021Pooled it
- The Impact of Preoperative Sarcopenia on Survival Prognosis in Patients Receiving Neoadjuvant Therapy for Esophageal Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Radiologically Determined Sarcopenia Predicts Morbidity and Mortality Following Abdominal Surgery: A Systematic Review and Meta-Analysis.World journal of surgery · 2017Pooled it
- Trial
- Linking the Planetary Health Diet Index to sarcopenia: the mediating effect of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR).Frontiers in nutrition · 2025Article
- Gastric Cancer with Sarcopenia: an Area Worth Focusing On.Current treatment options in oncology · 2023Review
- Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib.Thoracic cancer · 2023Article
- CT-based assessment of sarcopenia for differentiating wild-type from mutant-type gastrointestinal stromal tumor.Scientific reports · 2023Article
- Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST.BMC gastroenterology · 2022Article
- Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors.Journal of bone oncology · 2022Article
- Sarcopenia as a novel prognostic factor in the patients of primary localized gastrointestinal stromal tumor.BMC cancer · 2022Article
- Progress in Research on Antitumor Drugs and Dynamic Changes in Skeletal Muscles.Frontiers in pharmacology · 2022Review
- Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours.Frontiers in nutrition · 2022Article
- Article
- Cancer-Associated Muscle Wasting-Candidate Mechanisms and Molecular Pathways.International journal of molecular sciences · 2020Review
- Chemotherapy-Induced Sarcopenia.Current treatment options in oncology · 2020Review
- Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy.Cancer medicine · 2019Article
- Do we need a reference standard for the muscle mass measurements?ESC heart failure · 2018Article
- Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018.Journal of cachexia, sarcopenia and muscle · 2018Article
- Casting the net broader to confirm our imaginations: the long road to treating wasting disorders.Journal of cachexia, sarcopenia and muscle · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImatinib is a long-term, oral, targeted therapy for high-risk resected and advanced gastrointestinal stromal tumours (GIST). It is known that sarcopenia affects prognosis and treatment tolerance in patients with various solid cancers. We analysed lumbar skeletal muscle index changes in imatinib-treated GIST patients. Imatinib tolerance was also assessed to evaluate the influence of pre-treatment sarcopenia.
methodsThirty-one patients with advanced (n = 16) or high-risk resected (n = 15) GIST treated with imatinib (400 mg/day) were analysed retrospectively. Lumbar skeletal muscle indexes were evaluated on computed tomography images obtained before starting imatinib for all patients and at 6 months for those initially sarcopenic. Sarcopenia was defined using consensual cutoffs. Imatinib-induced toxicities were assessed after 3 months of administration.
resultsTwelve (38.7%) of the 31 patients were sarcopenic, including one unassessable at 6 months. Seven (63.6%) of the 11 assessable sarcopenic patients became non-sarcopenic after 6 months of imatinib. Pre-treatment sarcopenia was not associated with grades 3-4 toxicities, but the mean number of all-grade toxicities per sarcopenic patient was significantly higher for those non-sarcopenic (4.1 vs. 1.7, respectively, p < 0.01) after 3 months of treatment. Grades 1-2 anaemia and grades 1-2 fatigue were more frequent for sarcopenic than non-sarcopenic patients (83% vs. 26%, P < 0.01 and 42% vs. 5%, P = 0.02, respectively).
conclusionsSarcopenia is reversible in some GIST patients treated with imatinib. Pre-imatinib sarcopenia is predictive of non-severe toxicities, particularly anaemia and fatigue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.